We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




DNA Hypomethylation Predisposes to Type II Diabetes

By LabMedica International staff writers
Posted on 12 Jan 2012
A novel genomic screening technique that was used to compare DNA methylation variations between a group of individuals with type II diabetes and a group of normal individuals detected specific regions of hypomethylation in the DNA of the diabetes group.

Investigators at the Hebrew University of Jerusalem (Israel) designed a stepwise study to search for disease-contributing DNA methylation variations. More...
First, a pool based, genome-scale screen was carried out among 1169 type II diabetes cases and control individuals. Next, in-depth analyses were performed at selected top-ranking regions.

Results published in the January 15, 2012, online edition of the journal Human Molecular Genetics revealed an excess of differentially methylated sites in genomic regions that were previously associated with type II diabetes through genetic studies. A clear-cut region of hypomethylation was identified in the DNA of the type II diabetes cases relative to controls. The effect was independent of the sequence polymorphism in the region and persisted among individuals carrying the sequence-risk alleles. The odds of belonging to the type II diabetes group were increased by 6.1% for every 1% decrease in methylation.

A prospective study carried out in an independent population cohort revealed significant hypomethylation of young individuals that later progressed to type II diabetes, relative to the individuals who stayed healthy. Further genomic analysis revealed co-localization with gene enhancers and with binding sites for methylation-sensitive transcriptional regulators.

The data uncovered by this study showed that, “Low methylation levels at the analyzed sites were an early marker of type II diabetes and pointed to a novel mechanism by which early-onset, interindividual methylation variation at isolated nonpromoter genomic sites predisposes to type II diabetes.”

Related Links:

Hebrew University of Jerusalem




Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.